Opioid analgesic drugs are used with increasing frequency during surgical anaesthesia to control the endocrine and metabolic responses to stress (Hall, 1980) . Fentanyl, one of the more effective agents in this respect, is a lipid-soluble agonist of high intrinsic activity with ready access to the brain and opioid receptor sites. It produces a rapid and dose-dependent clinical response which reaches the maximum attainable for this class of drug. However, in the absence of other anaesthetic supplements, the dose of fentanyl required to achieve full analgesia is 25 (.ig kg" 1 or higher and the ensuing postoperative respiratory depression reduces the clinical benefit of its intraoperative use (Cooper et al., 1981) . Pharmacological control of this respiratory depression which allows adequate postoperative analgesia would extend the intraoperative use of opioid anaesthesia.
Buprenorphine is a partial agonist, also of high lipid solubility and receptor affinity but of a lower intrinsic activity (Dum and Herz, 1981) . This and other features of its actions have restricted its application in intraoperative anaesthesia, although as an analgesic for postoperative use its efficacy is well recognized (Harcus, Ward and Smith, 1980; Ellis et al., 1982) . Buprenorphine is also slow to reach its full effect, but once established it has a long duration of effect resistant to antagonism with naloxone (Orwin, 1977; Gibbs, Johnson and Davis, 1982) .
We have conducted a series of in vitro experiments to examine individual and interactive receptor binding properties of these two compounds in an attempt to understand possible receptor mechanisms which may mediate the different clinical effects of these drugs. 
MATERIALS AND METHODS

Opioid receptor binding assay
Male Wistar rat (250-300 g) forebrain (whole brain minus brainstem and cerebellum) was used as a source of opioid receptors. Rats were decapitated and the tissue rapidly dissected, weighed, placed in 30 volumes of Tris HC1 buffer (50 mmol litre ', pH 7.4 at 20 °C), and homogenized with an UltraTurrax superspeed homogenizer. The homogenate was resuspended in 30 volumes of Tris buffer, incubated in a shaking water-bath at 37 °C for 30 min, recentrifuged and resuspended in 50 volumes of Tris buffer. Ligand binding assays were performed as described previously (Villiger and Taylor, 1981, 1982) . Tubes contained 1.0 ml of membrane preparation (20 mg wet weight), 20-100 ulitre [
3 H]buprenorphine (30 Ci mmol" 1 ; Radiochemical Centre, Amersham) or [
3 H]fentanyl (12.4 Ci mmol" 1 ; Janssen Pharmaceutica, Beerse, Belgium), 20-100 ulitre drug (where applicable) and Tris buffer to give a final incubation volume of 2.0 ml. Following incubation at 25°C for 30 min, bound was separated from free [ 3 H]opioid by rapid filtration through Whatman GF/B glass fibre filters using a Millipore vacuum manifold. The filters were then removed carefully, dried and placed in vials to which 8.0 ml of a toluene-Triton X-100 scintillation cocktail was added, and radioactivity from labelled opioid was estimated by liquid scintillation spectrometry at a counting efficiency of 28-30%.
Non-specific binding was defined as that occurring in the presence of buprenorphine 1. 1 respectively. Dissociation kinetics were analysed using computerized non-linear regression analysis (Sedman and Wagner, 1974) . 
RESULTS
Binding affinities and binding sites
Buprenorphine's action on [ 3 H]fentanyl binding (a) Fentanyl displacement by addition of buprenorphine. After 30 min equilibration, [
3 H]fentanyl 2 nmol litre"' binding showed a biphasic, dosedependent dissociation following the addition of buprenorphine 1, 2 or 4 nmol litre"'. Thirty minutes after the introduction of buprenorphine, 67%, 60% and 38% of the fentanyl remained bound for each of the buprenorphine solutions, respectively. At 2 h the amount remaining bound was 48%, 30% and 9% for the same solutions ( fig. 3) [^H] fentanyl. On the basis of these studies, buprenorphine was two to three times more potent than fentanyl in displacing tritiated fentanyl 2.0 nmol litre ' from u receptors. The respective molar concentrations giving 50% inhibition of 
DISCUSSION
The distinction between agonist and agonistantagonist response profiles is not sufficient to explain many of the clinical features of fentanyl and buprenorphine. Buprenorphine has a high lipid solubility (log of the partition coefficient between heptane and 0.1-M phosphate buffer pH 7.4 = 1.78 (Hambrook and Ranee, 1976) ), as does fentanyl (log of the partition coefficient between octanol and water at pH 7.4 = 2.98 (Leysen, Gommern and Niemegeers, 1983) ), making for ready CNS access, so the slow onset of the action of buprenorphine is attributable probably to pharmacodynamic rather than pharmacokinetic factors. The observed in vitro studies showing that it took 10 min to establish .drug-receptor equilibrium with fentanyl, compared with 30 min for buprenorphine could explain, in part, their temporal differences in attaining full analgesic efficacy.
Our results indicate also that buprenorphine binds to four times the number of receptors labelled by fentanyl. This is consistent with the idea that fentanyl has selective affinity for morphine (u) recep-tors (Villiger, Ray and Taylor, 1983) while buprenorphine is comparatively non-selective, binding to \i, o (enkephalin) and K (benzomorphan) sites (Villiger and Taylor, 1981; Wood, 1982; Villiger, 1984) . Analgesia in clinical situations may be mediated by actions at the high affinity ui sites as proposed by Wolozin and Pasternak (1981) . Binding of buprenorphine to other opioid receptors may be less important in generating analgesia, but may bring about the observed antagonistic responses, for example actions on the K receptor being antagonistic to (.i receptor effects (Sadee, Rosenbaum and Herz, 1982) .
Duration of action for most agents is a function of their plasma concentration, response times reflecting their fate in the body as they are distributed, metabolized or excreted. Fentanyl responses parallel plasma concentration (Stoeckel et al., 1982) , but this is not so for buprenorphine, the actions of which (6 h or more (Cowan, Lewis and Macfarlane, 1977) ) extend well beyond plasma half-life times of 3-5 h (Bullingham, McQuay and Moore, 1983) . Although pharmacokinetic factors could account for this in part 5 the distinction might be explained further by differences observed with in vitro binding. Fentanyl dissociation is both rapid and almost complete, while that for buprenorphine is both very slow and incomplete, 50% of the drug remaining bound 1 h after attempted washout. This sluggish dissociation of buprenorphine from opioid receptors may account for the inability of naloxone to reverse established buprenorphine effects. The IC 50 for naloxone displacing [
3 H]buprenorphine is approximately 100 nmol litre"" 1 (Villiger and Taylor, 1981) , while only 2.5-nmol litre" 1 solutions of naloxone are needed to produce 50% inhibition of [ 3 H]fentanyl binding (Villiger, Ray and Taylor, 1983) . On this basis, 40 times the dose of naloxone would be needed to reverse comparable concentrations of buprenorphine as opposed to fentanyl receptor binding.
When utilized concurrently, the kinetics of fentanyl dissociation will depend on the dose of buprenorphine introduced and the timing of administration. Based on these in vitro studies, concurrent buprenorphine use at a concentration of 4 nmol litre"' (or approx. 2 ng ml" 1 ) will effectively displace 90% of bound fentanyl 2 nmol litre" 1 or 0.7 ng litre~' within 2 h. If the buprenorphine precedes fentanyl administration, buprenorphine 2.0 nmol litre" 1 can suppress almost completely any subsequent binding of equimolar concentrations of fentanyl. These values are within the ranges of plasma concentrations associated with the use of these drugs in clinical practice. How plasma concentrations relate to concentrations at opioid receptor sites is not known.
Distinctions in.receptor binding may potentially explain several aspects of clinical experience with buprenorphine and fentanyl. In particular, their pharmacodynamic differences in in vitro receptor binding offer explanations for temporal differences in onset and duration of action as well as their reversal characteristics with naloxone. Further application in combined sequences may have bearing on the use of buprenorphine for treatment of drug withdrawal effects (Jasinski, 1981) and in the reversal of acute opioid effects, as suggested by De Castro (1979), who proposed buprenorphine as an antagonist to fentanyl anaesthesia.
